Tags

Type your tag names separated by a space and hit enter

Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals.
J Infect. 2022 04; 84(4):579-613.JI

Links

PMC Free PDF

Authors+Show Affiliations

Faustini S
Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: s.e.faustini@bham.ac.uk.
Shields A
Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; University Hospitals Birmingham National Health Service (NHS) Foundation Trust, Birmingham, United Kingdom. Electronic address: a.m.shields@bham.ac.uk.
Banham G
Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; University Hospitals Birmingham National Health Service (NHS) Foundation Trust, Birmingham, United Kingdom. Electronic address: emma.banham@nhs.net.
Wall N
Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; University Hospitals Birmingham National Health Service (NHS) Foundation Trust, Birmingham, United Kingdom. Electronic address: nadya.wall@nhs.net.
Al-Taei S
Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: s.al-taei@bham.ac.uk.
Tanner C
Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: c.l.tanner@bham.ac.uk.
Ahmed Z
Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: a.zahra@bham.ac.uk.
Efstathiou E
Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: e.efstathiou@bham.ac.uk.
Townsend N
Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: n.j.townsend@bham.ac.uk.
Goodall M
Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: dm.goodall@bham.ac.uk.
Plant T
Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: tplant.1@bham.ac.uk.
Perez-Toledo M
Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: m.perez-toledo@bham.ac.uk.
Jasiulewicz A
Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: a.jasiulewicz@bham.ac.uk.
Price R
Biomedical Sciences Research Institute, Ulster University, Northern Ireland. Electronic address: rk.price@ulster.ac.uk.
McLaughlin J
Nanotechnology and Integrated Bioengineering Centre, Ulster University, Northern Ireland. Electronic address: jad.mclaughlin@ulster.ac.uk.
Farnan J
The Group Surgery, 257 North Queen Street, Belfast, Northern, Ireland. Electronic address: john.farnan@doctors.org.uk.
Moore J
Biomedical Sciences Research Institute, Ulster University, Northern Ireland. Electronic address: Moore-J66@ulster.ac.uk.
Robertson L
Biomedical Sciences Research Institute, Ulster University, Northern Ireland. Electronic address: lrobertson@ulster.ac.uk.
Nesbit A
Biomedical Sciences Research Institute, Ulster University, Northern Ireland. Electronic address: a.nesbit@ulster.ac.uk.
Curry G
Biomedical Sciences Research Institute, Ulster University, Northern Ireland. Electronic address: G.Curry@ulster.ac.uk.
Black A
The Group Surgery, 257 North Queen Street, Belfast, Northern, Ireland. Electronic address: AmyBlack@doctors.org.uk.
Cunningham A
Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: a.f.cunningham@bham.ac.uk.
Harper L
University Hospitals Birmingham National Health Service (NHS) Foundation Trust, Birmingham, United Kingdom; Institute of Applied Health, University of Birmingham, Birmingham, United Kingdom. Electronic address: lharper@bham.ac.uk.
Moore T
Biomedical Sciences Research Institute, Ulster University, Northern Ireland; Nanotechnology and Integrated Bioengineering Centre, Ulster University, Northern Ireland; Avellino labs USA 1505 Adams Drive Menlo Park, CA 94025 USA. Electronic address: tara.moore@ulster.ac.uk.
Drayson M
Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. Electronic address: m.t.drayson@bham.ac.uk.
Richter A
Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; University Hospitals Birmingham National Health Service (NHS) Foundation Trust, Birmingham, United Kingdom. Electronic address: a.g.richter@bham.ac.uk.

MeSH

Antibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesGlycoproteinsHumansSARS-CoV-2Spike Glycoprotein, Coronavirus

Pub Type(s)

Letter
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

35016901

Citation

Faustini, Sian, et al. "Cross Reactivity of Spike Glycoprotein Induced Antibody Against Delta and Omicron Variants Before and After Third SARS-CoV-2 Vaccine Dose in Healthy and Immunocompromised Individuals." The Journal of Infection, vol. 84, no. 4, 2022, pp. 579-613.
Faustini S, Shields A, Banham G, et al. Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals. J Infect. 2022;84(4):579-613.
Faustini, S., Shields, A., Banham, G., Wall, N., Al-Taei, S., Tanner, C., Ahmed, Z., Efstathiou, E., Townsend, N., Goodall, M., Plant, T., Perez-Toledo, M., Jasiulewicz, A., Price, R., McLaughlin, J., Farnan, J., Moore, J., Robertson, L., Nesbit, A., ... Richter, A. (2022). Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals. The Journal of Infection, 84(4), 579-613. https://doi.org/10.1016/j.jinf.2022.01.002
Faustini S, et al. Cross Reactivity of Spike Glycoprotein Induced Antibody Against Delta and Omicron Variants Before and After Third SARS-CoV-2 Vaccine Dose in Healthy and Immunocompromised Individuals. J Infect. 2022;84(4):579-613. PubMed PMID: 35016901.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals. AU - Faustini,Sian, AU - Shields,Adrian, AU - Banham,Gemma, AU - Wall,Nadezhda, AU - Al-Taei,Saly, AU - Tanner,Chloe, AU - Ahmed,Zahra, AU - Efstathiou,Elena, AU - Townsend,Neal, AU - Goodall,Margaret, AU - Plant,Tim, AU - Perez-Toledo,Marisol, AU - Jasiulewicz,Aleksandra, AU - Price,Ruth, AU - McLaughlin,James, AU - Farnan,John, AU - Moore,Julie, AU - Robertson,Louise, AU - Nesbit,Andrew, AU - Curry,Grace, AU - Black,Amy, AU - Cunningham,Adam, AU - Harper,Lorraine, AU - Moore,Tara, AU - Drayson,Mark, AU - Richter,Alex, Y1 - 2022/01/10/ PY - 2021/12/31/received PY - 2022/01/04/accepted PY - 2022/1/13/pubmed PY - 2022/4/14/medline PY - 2022/1/12/entrez KW - COVID-19 KW - Chronic kidney disease KW - Cross reactivity KW - Delta KW - Haemodialysis KW - Omicron KW - SARS-CoV-2 KW - Variants of Concern KW - antibody response KW - vaccination SP - 579 EP - 613 JF - The Journal of infection JO - J Infect VL - 84 IS - 4 SN - 1532-2742 UR - https://www.unboundmedicine.com/medline/citation/35016901/Cross_reactivity_of_spike_glycoprotein_induced_antibody_against_Delta_and_Omicron_variants_before_and_after_third_SARS_CoV_2_vaccine_dose_in_healthy_and_immunocompromised_individuals_ DB - PRIME DP - Unbound Medicine ER -